The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a retrospective analysis using the VALIDATE database, which aimed to compare the efficacy of the two currently FDA-approved hypomethylating agents (HMA), azacitidine and decitabine, in treating patients with higher-risk myelodysplastic syndromes (HR-MDS). No significant difference in overall survival (OS) was found between the two agents. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
